Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19433075 | 1.00 | MAPT (0.49) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL18840218 | 1.00 | MAPT (0.49) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2043782 | 0.83 | MAPT (0.43) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2043783 | 0.83 | MAPT (0.43) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9899496 | 0.82 | KDM4E (0.45) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9899495 | 0.82 | KDM4E (0.45) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL19559921 | 0.82 | MAPT (0.39) | MAPTKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL18840185 | 0.81 | ALDH1A1 (0.43) | MAPTKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL12082147 | 0.80 | MAPT (0.48) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2366519 | 0.80 | MAPT (0.48) | MAPTKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227018-B1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | UNIV VIRGINIA COMMONWEALTH (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| EP-2298761-B1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-25 | — | — | EP | disclosed |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-12-21 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-8828982-B2 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAPT 4242/4885KDM4E 2092/4885ALDH1A1 3445/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | MAPT 3887/4885KDM4E 2891/4885ALDH1A1 188/4885 |
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | WASF2, SCO2, SOD1 | MAPT 2594/4885KDM4E 2360/4885ALDH1A1 2424/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | MAPT 989/4885KDM4E 798/4885ALDH1A1 2133/4885 |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | WASF2, SOD1, CD274 | MAPT 2583/4885KDM4E 2245/4885ALDH1A1 2403/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | MAPT 4688/4885KDM4E 3601/4885ALDH1A1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.